Codexis Partners with Nitto Denko Avecia to Revolutionize Oligonucleotide Therapeutic Manufacturing

Codexis and Nitto Denko Avecia Forge Strategic Partnership for Enhanced Therapeutic Manufacturing

Codexis, Inc., a leader in enzymatic solutions for therapeutic manufacturing, announces a significant evaluation agreement with Nitto Denko Avecia, Inc., a well-renowned contract development and manufacturing organization (CDMO) specializing in oligonucleotide therapeutics. This collaboration centers around Codexis' innovative ECO Synthesis® Manufacturing Platform, which seeks to revolutionize the oligonucleotide synthesis process. By leveraging a flexible, enzyme-catalyzed approach, the platform aims to improve both scalability and sustainability, presenting a marked departure from traditional solid-phase synthesis methods that currently dominate the industry.

Stephen Dilly, Chairman and CEO of Codexis, expresses optimism about the partnership, underscoring its potential to broaden the reach of their advanced platform through strategic alliances with leading CDMOs. The agreement not only aligns with Codexis' mission to redefine therapeutic development but also positions the company to enhance its role in the evolving landscape of drug manufacturing. By focusing on sustainable and scalable solutions, Codexis aims to meet the growing global demand for high-quality therapeutics, particularly in the realm of small interfering RNA (siRNA) production, which is becoming increasingly vital in modern medicine.

Nitto Denko Avecia, known for its expertise in manufacturing a vast array of oligonucleotide sequences, brings valuable experience to this collaboration. With facilities located in Milford, MA, and Cincinnati, OH, the organization has successfully catered to both preclinical and commercial needs, manufacturing over 1,500 oligonucleotide sequences to date. The partnership with Codexis marks a pivotal moment in the quest for more efficient production methods that can ultimately enhance the quality and availability of therapeutic solutions for patients worldwide. Together, these companies strive to push the boundaries of therapeutic manufacturing while adhering to stringent quality standards.

In addition to the partnership, Codexis continues to emphasize its commitment to being a long-term partner in the healthcare ecosystem, focusing on innovation and scientific expertise. The collaboration with Nitto Denko Avecia reflects a shared vision of pioneering next-generation manufacturing technologies that can transform therapeutic development and delivery.

As the demand for oligonucleotide therapeutics grows, this partnership represents a crucial step towards developing high-quality, efficient manufacturing processes that can effectively serve the needs of healthcare providers and patients alike. The advancements from this collaboration may set a new standard in the industry, offering a sustainable approach to therapeutic manufacturing that aligns with global healthcare goals.